Welcome to Global Market Bulletin TV, where host Leyla Gulen brings you exclusive access to the innovators reshaping the future of global health and biotechnology. In this special episode, we sit down with Geert Kersten, Chief Executive Officer of CEL-SCI Corporation (NASDAQ: CVM), a pioneering biotech company redefining the possibilities of cancer immunotherapy through decades of research, dedication, and scientific leadership.

In this rare and in-depth conversation, Geert Kersten walks us through CEL-SCI’s mission to transform the treatment of head and neck cancer through its flagship immunotherapy candidate, Multikine®. Kersten explains how Multikine’s unique mechanism—priming the immune system before surgery and radiotherapy—represents a paradigm shift in cancer treatment, potentially improving survival rates by empowering the body’s natural defense system at the most critical moment.

A central focus of the interview is CEL-SCI’s important presentation at the European Society for Radiotherapy and Oncology (ESTRO) 2023 Congress in Vienna, Austria. Kersten highlights the compelling histopathology data that confirmed Multikine’s ability to significantly prolong overall survival in head and neck cancer and increase five-year survival for specific patient subgroups. He also discusses data showing improved progression-free survival and a notably reduced death rate among Multikine-treated patients compared to those receiving standard of care alone—results that have attracted global scientific and clinical attention.

Kersten also shares updates from CEL-SCI’s productive pre-submission meeting with Health Canada, where regulators provided constructive guidance on the best path forward for potential market approval. This represents an important regulatory milestone as CEL-SCI advances toward the next stage in bringing Multikine to patients in need.

Throughout the interview, Kersten’s deep knowledge of immunotherapy, regulatory strategy, and biotech development shines through. His commentary provides valuable context on how cancer treatment is evolving, why immune-priming therapies like Multikine could mark the next frontier, and how CEL-SCI is positioning itself at the forefront of this transformation.

This episode is essential viewing for healthcare professionals, scientists, biotech investors, and anyone passionate about the future of cancer treatment. It offers a front-row look at a company pushing the boundaries of medical innovation and a CEO determined to bring life-changing therapies to the patients who need them most.

Make sure to Subscribe to Global Market Bulletin TV and turn on notifications to stay ahead of breaking interviews, biotech insights, and executive-level conversations that shape the global markets. Don’t miss this deep dive into CEL-SCI’s groundbreaking work and the future of cancer immunotherapy.

CHECK THIS OUT: Why Nebius (NBIS) Could Outperform CoreWeave & Dominate the $9B AI Infrastructure Market and Is Lucid Group (LCID) Running Out of Cash? $875M Note Deal Raises Alarms.

About CEL-SCI Corporation (NASDAQ: CVM)

CEL-SCI Corporation is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies that enable the immune system to fight cancer more effectively. At the core of CEL-SCI’s work is Multikine® (Leukocyte Interleukin, Injection), a first-of-its-kind investigational immunotherapy designed to stimulate the immune response before standard cancer treatment begins. Multikine is being developed as a potential first-line therapy for patients with squamous cell carcinoma of the head and neck, one of the most lethal and underserved cancers worldwide.

The company’s breakthrough lies in its unique approach: instead of treating cancer after significant immune damage has occurred, Multikine is administered before surgery and radiation, when the immune system is strongest and most capable of mounting a robust anti-tumor response. Clinical data to date suggests that this approach may improve survival outcomes and reduce disease progression for select patient subgroups.

Beyond Multikine, CEL-SCI continues to explore immunotherapy applications across oncology and immune-related conditions. With a global network of research partnerships, regulatory initiatives, and clinical studies, the company remains committed to delivering transformative therapies that address significant unmet medical needs.

READ ALSO: Above Food (ABVE) to Issue 1.1 Billion New Shares in Merger and Perpetua Resources (PPTA) Soars 171% as U.S. Approves $1.3B Gold-Antimony Mine.